117. Cancer Discov. 2018 Jul;8(7):784. doi: 10.1158/2159-8290.CD-NB2018-067. Epub 2018May 18.Shorter Trastuzumab Course Still Effective.[No authors listed]Reducing the duration of trastuzumab treatment may be beneficial for women withHER2-positive breast cancer: In the phase III PERSEPHONE trial, women whoreceived the drug for 6 months had a similar rate of disease-free survival aswomen on a 12-month course, but were half as likely to stop treatment due tocardiac side effects.Â©2018 American Association for Cancer Research.DOI: 10.1158/2159-8290.CD-NB2018-067 PMID: 29776911 